{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:19:57Z","timestamp":1785907197372,"version":"3.56.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40120-023-00460-1","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:25:14Z","timestamp":1679876714000},"page":"795-814","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Estimated Societal Value of Lecanemab in Patients with Early Alzheimer\u2019s Disease Using Simulation Modeling"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4003-3192","authenticated-orcid":false,"given":"Amir Abbas","family":"Tahami Monfared","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weicheng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Sardesai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Folse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameya","family":"Chavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanwu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"issue":"1","key":"460_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12929-019-0609-7","volume":"27","author":"LK Huang","year":"2020","unstructured":"Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020;27(1):18.","journal-title":"J Biomed Sci"},{"issue":"4","key":"460_CR2","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/alz.12638","volume":"18","author":"The Alzheimer's Association","year":"2022","unstructured":"The Alzheimer\u2019s Association. 2022 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2022;18(4):700\u201389.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"460_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13195-022-01053-0","volume":"14","author":"A Mank","year":"2022","unstructured":"Mank A, van Maurik IS, Rijnhart JJM, Bakker ED, Bouteloup V, Le Scouarnec L, et al. Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14(1):110.","journal-title":"Alzheimers Res Ther"},{"key":"460_CR4","doi-asserted-by":"crossref","unstructured":"Frisoni G. Structural imaging in the clinical diagnosis of Alzheimer's disease: problems and tools. BMJ Publishing Group Ltd; 2001;711\u20138.","DOI":"10.1136\/jnnp.70.6.711"},{"issue":"2","key":"460_CR5","first-page":"109","volume":"4","author":"J Cummings","year":"2017","unstructured":"Cummings J, Fox N. Defining disease modifying therapy for Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2017;4(2):109\u201315.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"460_CR6","volume":"7","author":"J Cummings","year":"2021","unstructured":"Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer\u2019s disease drug development pipeline: 2021. Alzheimers Dement (NY). 2021;7(1): e12179.","journal-title":"Alzheimers Dement (NY)"},{"issue":"1","key":"460_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"460_CR8","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40120-022-00350-y","volume":"11","author":"AA Tahami Monfared","year":"2022","unstructured":"Tahami Monfared AA, Tafazzoli A, Ye W, Chavan A, Zhang Q. Long-term health outcomes of lecanemab in patients with early Alzheimer\u2019s disease using simulation modeling. Neurol Therapy. 2022;11(2):863\u201380.","journal-title":"Neurol Therapy"},{"issue":"3","key":"460_CR9","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40120-022-00373-5","volume":"11","author":"AA Tahami Monfared","year":"2022","unstructured":"Tahami Monfared AA, Tafazzoli A, Chavan A, Ye W, Zhang Q. The potential economic value of lecanemab in patients with early Alzheimer\u2019s disease using simulation modeling. Neurol Therapy. 2022;11(3):1285\u2013307.","journal-title":"Neurol Therapy"},{"issue":"1","key":"460_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther. 2021;13(1):80.","journal-title":"Alzheimers Res Ther"},{"key":"460_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2020.102346","volume":"72","author":"DN Lakdawalla","year":"2020","unstructured":"Lakdawalla DN, Phelps CE. Health technology assessment with risk aversion in health. J Health Econ. 2020;72: 102346.","journal-title":"J Health Econ"},{"key":"460_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.trci.2018.01.001","volume":"4","author":"AR Kansal","year":"2018","unstructured":"Kansal AR, Tafazzoli A, Ishak KJ, Krotneva S. Alzheimer\u2019s disease Archimedes condition-event simulator: development and validation. Alzheimers Dement (N Y). 2018;4:76\u201388.","journal-title":"Alzheimers Dement (N Y)"},{"key":"460_CR13","unstructured":"Tafazzoli A, Weng J, Sutton K. Validating simulated cognition trajectories based on ADNI against trajectories from the National Alzheimer's Coordinating Center (NACC) dataset of Clinical Trials on Alzheimer's Disease (CTAD). 2018."},{"issue":"7","key":"460_CR14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s40273-016-0392-1","volume":"34","author":"L Hernandez","year":"2016","unstructured":"Hernandez L, Ozen A, DosSantos R, Getsios D. Systematic review of model-based economic evaluations of treatments for Alzheimer\u2019s disease. Pharmacoeconomics. 2016;34(7):681\u2013707.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"460_CR15","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1177\/0272989X12454577","volume":"32","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM modeling good research practices task force\u20131. Med Decis Making. 2012;32(5):667\u201377.","journal-title":"Med Decis Making"},{"key":"460_CR16","unstructured":"Alzheimer's disease neuroimaging initiative [Internet]. 2017. Available from: https:\/\/adni.loni.usc.edu\/."},{"issue":"5","key":"460_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2165\/11531870-000000000-00000","volume":"28","author":"D Getsios","year":"2010","unstructured":"Getsios D, Blume S, Ishak KJ, Maclaine GD. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer\u2019s disease. Pharmacoeconomics. 2010;28(5):411\u201327.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"460_CR18","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s40273-014-0203-5","volume":"32","author":"S Guo","year":"2014","unstructured":"Guo S, Getsios D, Revankar N, Xu P, Thompson G, Bobula J, et al. Evaluating disease-modifying agents: a simulation framework for Alzheimer\u2019s disease. Pharmacoeconomics. 2014;32(11):1129\u201339.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"460_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1046\/j.1532-5415.2002.50065.x","volume":"50","author":"GW Small","year":"2002","unstructured":"Small GW, McDonnell DD, Brooks RL, Papadopoulos G. The impact of symptom severity on the cost of Alzheimer\u2019s disease. J Am Geriatr Soc. 2002;50(2):321\u20137.","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"460_CR20","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103.","journal-title":"JAMA"},{"issue":"8","key":"460_CR21","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/archneur.65.8.1091","volume":"65","author":"SE O\u2019Bryant","year":"2008","unstructured":"O\u2019Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, et al. Staging dementia using clinical dementia rating scale sum of boxes scores: a Texas Alzheimer\u2019s research consortium study. Arch Neurol. 2008;65(8):1091\u20135.","journal-title":"Arch Neurol"},{"key":"460_CR22","unstructured":"Arias E, Xu J, Kochanek KD. United States life tables, 2016. 2019."},{"issue":"1","key":"460_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000265553","volume":"29","author":"K Andersen","year":"2010","unstructured":"Andersen K, Lolk A, Martinussen T, Kragh-S\u00f8rensen P. Very mild to severe dementia and mortality: a 14-year follow-up\u2013the Odense study. Dement Geriatr Cogn Disord. 2010;29(1):61\u20137.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"3","key":"460_CR24","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3233\/JAD-191055","volume":"75","author":"A Wimo","year":"2020","unstructured":"Wimo A, Handels R, Winblad B, Black CM, Johansson G, Salomonsson S, et al. Quantifying and describing the natural history and costs of Alzheimer\u2019s disease and effects of hypothetical interventions. J Alzheimers Dis. 2020;75(3):891\u2013902.","journal-title":"J Alzheimers Dis"},{"key":"460_CR25","doi-asserted-by":"crossref","unstructured":"Neumann PJ, Hermann R, Kuntz K, Araki S, Duff S, Leon J, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer\u2019s disease. Neurology. 1999;52(6):1138.","DOI":"10.1212\/WNL.52.6.1138"},{"issue":"8","key":"460_CR26","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2174\/1567205015666180119092427","volume":"15","author":"M Davis","year":"2018","unstructured":"Davis M, O\u2019Connell T, Johnson S, Cline S, Merikle E, Martenyi F, et al. Estimating Alzheimer\u2019s disease progression rates from normal cognition through mild cognitive impairment and stages of dementia. Curr Alzheimer Res. 2018;15(8):777\u201388.","journal-title":"Curr Alzheimer Res"},{"key":"460_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101339","volume":"68","author":"KI Avgerinos","year":"2021","unstructured":"Avgerinos KI, Ferrucci L, Kapogiannis D. Effects of monoclonal antibodies against amyloid-\u03b2 on clinical and biomarker outcomes and adverse event risks: a systematic review and meta-analysis of phase III RCTs in Alzheimer\u2019s disease. Ageing Res Rev. 2021;68: 101339.","journal-title":"Ageing Res Rev"},{"key":"460_CR28","first-page":"382","volume":"10","author":"E Fletcher","year":"2018","unstructured":"Fletcher E, Filshtein TJ, Harvey D, Renaud A, Mungas D, DeCarli C, et al. Staging of amyloid \u03b2, t-tau, regional atrophy rates, and cognitive change in a nondemented cohort: results of serial mediation analyses. Alzheimer\u2019s Demen Diagnos Assess Dis Monit. 2018;10:382\u201393.","journal-title":"Alzheimer's Demen Diagnos Assess Dis Monit"},{"issue":"1","key":"460_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","volume":"14","author":"E McDade","year":"2022","unstructured":"McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M, et al. Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022;14(1):191.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"460_CR30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13195-022-01129-x","volume":"14","author":"S Dhadda","year":"2022","unstructured":"Dhadda S, Kanekiyo M, Li D, Swanson CJ, Irizarry M, Berry S, et al. Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14(1):182.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"460_CR31","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3233\/JAD-191212","volume":"75","author":"RL Robinson","year":"2020","unstructured":"Robinson RL, Rentz DM, Andrews JS, Zagar A, Kim Y, Bruemmer V, et al. Costs of early stage Alzheimer\u2019s disease in the United States: cross-sectional analysis of a prospective cohort study (GERAS-US). J Alzheimers Dis. 2020;75(2):437\u201350.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"460_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3233\/JAD-122392","volume":"36","author":"A Wimo","year":"2013","unstructured":"Wimo A, Reed CC, Dodel R, Belger M, Jones RW, Happich M, et al. The GERAS study: a prospective observational study of costs and resource use in community dwellers with Alzheimer\u2019s disease in three European countries\u2013study design and baseline findings. J Alzheimers Dis. 2013;36(2):385\u201399.","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"460_CR33","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1377\/hlthaff.17.6.206","volume":"17","author":"J Leon","year":"1998","unstructured":"Leon J, Cheng C-K, Neumann PJ. Alzheimer\u2019s disease care: costs and potential savings: caring for persons with Alzheimer\u2019s disease in the community can save thousands of dollars, but at what cost to family caregivers? Health Aff. 1998;17(6):206\u201316.","journal-title":"Health Aff"},{"key":"460_CR34","unstructured":"The Alzheimer's Association. Changing the trajectory of Alzheimer\u2019s disease: how a treatment by 2025 saves lives and dollars. Appendix A: Methodology. 2015."},{"key":"460_CR35","unstructured":"Cost of Care Survey 2022 [Internet]. Available from: https:\/\/www.genworth.com\/aging-and-you\/finances\/cost-of-care.html."},{"issue":"1","key":"460_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-020-00659-6","volume":"12","author":"DB DiBenedetti","year":"2020","unstructured":"DiBenedetti DB, Slota C, Wronski SL, Vradenburg G, Comer M, Callahan LF, et al. Assessing what matters most to patients with or at risk for Alzheimer\u2019s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes. Alzheimer\u2019s Res Ther. 2020;12(1):1\u201315.","journal-title":"Alzheimer's Res Ther"},{"key":"460_CR37","unstructured":"Medicare Physician Fee Schedule. CY 2022 National Payment Amount by HCPCS Code 2022. [Internet]. 2022 [cited Apr 14, 2022]. Available from: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/PhysicianFeeSched."},{"key":"460_CR38","unstructured":"IBM Micromedex RED BOOK [Internet]. [cited Apr 14, 2022]. Available from: https:\/\/www.ibm.com\/products\/micromedex-red-book."},{"key":"460_CR39","unstructured":"Consumer price index [Internet]. [cited Apr 14, 2022]. Available from: https:\/\/www.bls.gov\/cpi\/."},{"issue":"1","key":"460_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-020-00723-1","volume":"12","author":"F Landeiro","year":"2020","unstructured":"Landeiro F, Mughal S, Walsh K, Nye E, Morton J, Williams H, et al. Health-related quality of life in people with predementia Alzheimer\u2019s disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review. Alzheimer\u2019s Res Ther. 2020;12(1):1\u201314.","journal-title":"Alzheimer's Res Ther"},{"key":"460_CR41","doi-asserted-by":"crossref","unstructured":"Neumann PJ, Kuntz KM, Leon J, Araki SS, Hermann RC, Hsu M-A, et al. Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers. Medical care. 1999:27\u201332.","DOI":"10.1097\/00005650-199901000-00005"},{"issue":"4","key":"460_CR42","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11136-010-9783-5","volume":"20","author":"R Xu","year":"2011","unstructured":"Xu R, Insinga RP, Golden W, Hu XH. EuroQol (EQ-5D) health utility scores for patients with migraine. Qual Life Res. 2011;20(4):601\u20138.","journal-title":"Qual Life Res"},{"issue":"4","key":"460_CR43","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2174\/156720510791162430","volume":"7","author":"J Mesterton","year":"2010","unstructured":"Mesterton J, Wimo A, Langworth S, Winblad B, Jonsson L. Cross sectional observational study on the societal costs of Alzheimer\u2019s disease. Curr Alzheimer Res. 2010;7(4):358\u201367.","journal-title":"Curr Alzheimer Res"},{"key":"460_CR44","doi-asserted-by":"crossref","unstructured":"Petersen RC, Aisen PS, Andrews JS, Atri A, Matthews BR, Rentz DM, et al. Expectations and clinical meaningfulness of randomized controlled trials. Alzheimers Dement. 2023.","DOI":"10.1002\/alz.12959"},{"issue":"10","key":"460_CR45","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaneurol.2015.1721","volume":"72","author":"SE Monsell","year":"2015","unstructured":"Monsell SE, Kukull WA, Roher AE, Maarouf CL, Serrano G, Beach TG, et al. Characterizing apolipoprotein E epsilon4 carriers and noncarriers with the clinical diagnosis of mild to moderate alzheimer dementia and minimal beta-amyloid peptide plaques. JAMA Neurol. 2015;72(10):1124\u201331.","journal-title":"JAMA Neurol"},{"issue":"6","key":"460_CR46","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/hec.1741","volume":"21","author":"N Hawkins","year":"2012","unstructured":"Hawkins N, Richardson G, Sutton AJ, Cooper NJ, Griffiths C, Rogers A, et al. Surrogates, meta-analysis and cost-effectiveness modelling: a combined analytic approach. Health Econ. 2012;21(6):742\u201356.","journal-title":"Health Econ"},{"issue":"4","key":"460_CR47","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/alz.12422","volume":"18","author":"DP Veitch","year":"2022","unstructured":"Veitch DP, Weiner MW, Aisen PS, Beckett LA, DeCarli C, Green RC, et al. Using the Alzheimer\u2019s disease neuroimaging initiative to improve early detection, diagnosis, and treatment of Alzheimer\u2019s disease. Alzheimers Dement. 2022;18(4):824\u201357.","journal-title":"Alzheimers Dement"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00460-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00460-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00460-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T08:49:46Z","timestamp":1684399786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00460-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["460"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00460-1","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"assertion":[{"value":"31 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}